Best Practice & Research Clinical Haematology
Volume 20, Issue 2 , Pages 247-263 , June 2007

Cardiac assessment of patients for haematopoietic stem cell transplantation

  • J.G. Coghlan, MD, FRCP (Consultant Cardiologist)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +44 207 7940500x38017.

References 

  1. Passweg J, Baldomero H, Chapuis B, et al. Swiss Transplant Working Group Blood and Marrow Transplantation Board. Haematopoietic stem cell transplantation in Switzerland. Report from the Swiss Transplant Working Group Blood and Marrow Transplantation (STABMT) Registry 1997–2003. Swiss Medical Weekly. 2006;136(3–4):50–58
  2. Morgan GW, McIlveen BM, Freedman A, et al. Radionuclide ejection fraction in doxorubicin cardiotoxicity. Cancer Treatment Reports. 1981;65(7–8):629–638
  3. Balducci L, Extermann M. Cancer chemotherapy in the older patient: what the medical oncologist needs to know. Cancer. 1997;80(7):1317–1322
  4. Gratwohl A, Baldomero H, Frauendorfer K, et al. EBMT activity survey 2004 and changes in disease indication over the past 15 years. Bone Marrow Transplantation. 2006;37(12):1069–1085
  5. Schonland SO, Lokhorst H, Buzyn A, et al. Chronic Leukemia Working Party; Myeloma Subcommittee of the European Cooperative Group for Blood and Marrow Transplantation Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation. Blood. 2006;107:2578–2584
  6. Nash RA, McSweeney PA, Nelson JL, et al. Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis. Arthritis and Rheumatism. 2006;54:1982–1986
  7. Gaziev J, Sodani P, Polchi P, et al. Bone marrow transplantation in adults with thalassemia: treatment and long-term follow-up. Annals of the New York Academy of Sciences. 2005;1054:196–205
  8. Vermylen C. Hematopoietic stem cell transplantation in sickle cell disease. Blood Reviews. 2003;17:163–166[Review]
  9. Boelens JJ. Trends in haematopoietic cell transplantation for inborn errors of metabolism. Journal of Inherited Metabolic Disease. 2006;29:413–420
  10. Buadi FK, Micallef IN, Ansell SM, et al. Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma. Bone Marrow Transplantation. 2006;37:1017–1022
  11. Working Group Report . How to diagnose diastolic heart failure. European Study Group on Diastolic Heart Failure. European Heart Journal. 1998;19(7):990–1003
  12. Murdych T, Weisdorf DJ. Serious cardiac complications during bone marrow transplantation at the University of Minnesota, 1977–1997. Bone Marrow Transplantation. 2001;28:283–287
  13. Bearman SI, Petersen FB, Schor RA, et al. Radionuclide ejection fractions in the evaluation of patients being considered for bone marrow transplantation: risk for cardiac toxicity. Bone Marrow Transplantation. 1990;5:173–177
  14. Cazin B, Gorin NC, Laporte JP, et al. Cardiac complications after bone marrow transplantation. A report on a series of 63 consecutive transplantations. Cancer. 1986;57:2061–2069
  15. Shapira MY, Resnick IB, Bitan M, et al. Low transplant-related mortality with allogeneic stem cell transplantation in elderly patients. Bone Marrow Transplantation. 2004;34:155–159
  16. Aoudjhane M, Labopin M, Gorin NC, et al. Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia. 2005 Dec;19(12):2304–2312
  17. von Bernuth G, Adam D, Hofstetter R, et al. Cyclophosphamide cardiotoxicity. European Journal of Pediatrics. 1980 Jun;134(1):87–90
  18. Mullins GM, Anderson PN, Santos GW. High dose cyclophosphamide therapy in solid tumors. Therapeutic, toxic, and immunosuppressive effects. Cancer. 1975 Dec;36(6):1950–1958
  19. Buja LM, Ferrans VJ, Graw RG. Cardiac pathologic findings in patients treated with bone marrow transplantation. Human Pathology. 1976 Jan;7(1):17–45
  20. Evans BD, Smith IE, Clutterbuck RD, et al. Prevention of acute deaths in mice after very high dose cyclophosphamide by divided dose schedule. British Journal of Cancer. 1984 Jan;49(1):43–47
  21. Taylor AL, Applefeld MM, Wiernik PH, et al. Acute anthracycline cardiotoxicity. Comparative morphologic study of three analogues. Cancer. 1984 Apr 15;53(8):1660–1666
  22. Buzdar AU, Kau SW, Smith TL, et al. Ten-year results of FAC adjuvant chemotherapy trial in breast cancer. American Journal of Clinical Oncology. 1989 Apr;12(2):123–128
  23. Doyle JJ, Neugut AI, Jacobson JS, et al. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. Journal of Clinical Oncology. 2005 Dec 1;23(34):8597–8605
  24. Nakamae H, Tsumura K, Terada Y, et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer. 2005 Dec 1;104(11):2492–2498
  25. Sudharsan PT, Mythili Y, Selvakumar E, et al. Lupeol and its ester ameliorate the cyclophosphamide provoked cardiac lysosomal damage studied in rat. Molecular and Cellular Biochemistry. 2006 Jan;282(1–2):23–29
  26. Dispenzieri A, Gertz M, Kyle R, et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2004;104:1181–1887
  27. Matta B, Stow P. Sepsis-induced vasoparalysis does not involve the cerebral vasculature; indirect evidence from autoregulation and carbon dioxide reactivity studies. British Journal of Anaesthesia. 1996;76:790–794
  28. Artucio H, Digenio A, Pereyra M. Left ventricular function during sepsis. Critical Care Medicine. 1989;17:323–327
  29. Weinberg J, Innes J, Thomas K, et al. Studies on the circulation in normotensive febrile patients. Quarterly Journal of Experimental Physiology. 1989;74:301–310
  30. Mackenzie I. The haemodynamics of human septic shock. Anaesthesia. 2001;56:130–144
  31. Young JB. Assessment of heart failure. In:  Colucci WS editors. Heart Failure: Cardiac Function and Dysfunction.  Braunwald E editors. Atlas of Heart Disease. 4:1995;p. 7.1–7.20
  32. Heidenreich PA, Spertus JA, Jones PG, et al. Health status identifies heart failure outpatients at risk for hospitalization or death. Journal of the American College of Cardiology. 2006 Feb 21;47(4):752–756
  33. van Heerebeek L, Borbely A, Niessen HW, et al. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation. 2006 Apr 25;113(16):1966–1973
  34. Choi BR, Kim JS, Yang YJ, et al. Factors associated with decreased cerebral blood flow in congestive heart failure secondary to idiopathic dilated cardiomyopathy. The American Journal of Cardiology. 2006 May 1;97(9):1365–1369
  35. Maurer MS, King DL, El-Khoury Rumbarger L, et al. Left heart failure with a normal ejection fraction: identification of different pathophysiologic mechanisms. Journal of Cardiac Failure. 2005;11:177–187
  36. Thomas MD, Fox KF, Wood DA, et al. Echocardiographic features and brain natriuretic peptides in patients presenting with heart failure and preserved systolic function. Heart. 2006 May;92(5):603–608
  37. Bertz H, Auner HW, Weissinger F, et al. Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Antimicrobial therapy of febrile complications after high-dose chemo-/radiotherapy and autologous hematopoietic stem cell transplantation—guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Annals of Hematology. 2003;82(supplement 2):S167–S174
  38. Suresh V, Khavani A, Hancock H. 5-flurouracil induced coronary artery vasospasm. Heart. 2004;90(4):439
  39. Galetta F, Franzoni F, Cervetti G, et al. Effect of epirubicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients. Biomedicine & Pharmacotherapy. 2005;59(10):541–544
  40. Solomon SD, Anavekar N, Skali H, et al. Candesartan in Heart Failure Reduction in Mortality (CHARM) Investigators. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation. 2005;112(24):3738–3744
  41. Sisakova M, Toman O, Florianova A, et al. Extension of QT interval as a consequence of risk factor accumulation – case study. Vnitrni Lekarstvi. 2006;52:271–273
  42. Moss AJ, Zareba W, Kaufman ES, et al. Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel. Circulation. 2002;105(7):794–799
  43. Ikeda T, Takami M, Sugi K, et al. Noninvasive risk stratification of subjects with a Brugada-type electrocardiogram and no history of cardiac arrest. Annals of Noninvasive Electrocardiology. 2005;10(4):396–403
  44. Hulot JS, Jouven X, Empana JP, et al. Natural history and risk stratification of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circulation. 2004;110(14):1879–1884
  45. Cecchi F, Olivotto I, Betocchi S, et al. The Italian registry for hypertrophic cardiomyopathy: a nationwide survey. American Heart Journal. 2005;150(5):947–954
  46. Yap YG, Camm AJ. Lessons from antiarrhythmic trials involving class III antiarrhythmic drugs. The American Journal of Cardiology. 1999;84(9A):83R–89R
  47. Lecomte D, Fornes P, Fouret P, et al. Isolated myocardial fibrosis as a cause of sudden cardiac death and its possible relation to myocarditis. Journal of Forensic Sciences. 1993;38(3):617–621
  48. Bardy GH, Lee KL, Mark DB, et al. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. The New England Journal of Medicine. 2005;352(3):225–237
  49. Blomstrom-Lundqvist C, Scheinman MM, Aliot EM, et al. European Society of Cardiology Committee, NASPE-Heart Rhythm Society. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias–executive summary. A report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with NASPE-Heart Rhythm Society. Journal of the American College of Cardiology. 2003;42(8):1493–1531
  50. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Annals of Oncology. 2002;13(5):699–709
  51. Pinarli FG, Oguz A, Tunaoglu FS, et al. Late cardiac evaluation of children with solid tumors after anthracycline chemotherapy. Pediatric Blood & Cancer. 2005;44(4):370–377
  52. Gharib MI, Burnett AK. Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. European Journal of Heart Failure. 2002 Jun;4(3):235–242
  53. Abali H, Oyan B, Koc Y, et al. IIVP salvage regimen induces high response rates in patients with relapsed lymphoma before autologous stem cell transplantation. American Journal of Clinical Oncology. 2005;28(3):264–269
  54. Buchner T, Berdel WE, Wormann B, et al. Treatment of older patients with AML. Critical Reviews in Oncology/Hematology. 2005;56(2):247–259
  55. Bernitsas E, Wei W, Mikol DD. Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane. Annals of Neurology. 2006 Jan;59(1):206–209
  56. Taniguchi I. Clinical significance of cyclophosphamide-induced cardiotoxicity. Internal Medicine. 2005 Feb;44(2):89–90
  57. Suter TM, Meier B. Detection of anthracycline-induced cardiotoxicity: is there light at the end of the tunnel?. Annals of Oncology. 2002 May;13(5):647–649
  58. Horacek JM, Pudil R, Tichy M, et al. The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia. Neoplasma. 2005;52(5):430–434
  59. Soker M, Kervancioglu M. Plasma concentrations of NT-pro-BNP and cardiac troponin-I in relation to doxorubicin-induced cardiomyopathy and cardiac function in childhood malignancy. Saudi Medical Journal. 2005 Aug;26(8):1197–1202
  60. Saccardi R, Tyndall A, Coghlan G, et al. Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis. Bone Marrow Transplantation. 2004;34(10):877–881
  61. Mukerjee D, St George D, Coleiro B, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Annals of the Rheumatic Diseases. 2003;62:1088–1093
  62. Hachulla E, Gressin V, Guillevin L, et al. Pulmonary arterial hypertension in systemic sclerosis: definition of a screening algorithm for early detection (ItinerAIR-Sclerodermie Study). [Article in French] La Revue de Medecine Interne. 2004;25(5):340–347
  63. Mayes MD, Lacey JV, Beebe-Dimmer J, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis and Rheumatism. 2003;48:2246–2255
  64. Yoshida A, Katayama M. Pulmonary hypertension in patients with connective tissue diseases. Nippon Rinsho. 2001;59(6):
  65. Winslow TM, Ossipov MA, Fazio GP, et al. Five year follow up study of the prevalence and progression of pulmonary hypertension in systemic lupus erythematosus. American Heart Journal. 1995;129:510–515
  66. Law WG, Thong BY, Lian TY, et al. Acute lupus myocarditis: clinical features and outcome of an oriental case series. Lupus. 2005;14(10):827–831
  67. Santoli F, Zerah F, Vasile N, et al. Pulmonary function in sickle cell disease with or without acute chest syndrome. The European Respiratory Journal. 1998;12:1124–1129
  68. Ataga KI, Sood N, De Gent G, et al. Pulmonary hypertension in sickle cell disease. The American Journal of Medicine. 2004;117(9):665–669
  69. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England Journal of Medicine. 2004 Feb 26;350(9):886–895
  70. Castro O, Hoque M, Brown BD. Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival. Blood. 2003;101(4):1257–1261
  71. Simmons BE, Santhanam V, Castaner A, et al. Sickle cell heart disease. Two-dimensional echo and Doppler ultrasonographic findings in the hearts of adult patients with sickle cell anemia. Archives of Internal Medicine. 1988;148(7):1526–1528
  72. Tap O, San M, Mete UO, et al. Ultrastructural alterations in the myocardium of patients with sickle cell anemia. Journal of Submicroscopic Cytology and Pathology. 2001;33(1–2):151–156
  73. Engle MA, Erlandson M, Smith CH. Late cardiac complications of chronic, refractory anemia with hemochromatosis. Circulation. 1964;30:698–705
  74. Aessopos A, Farmakis D, Deftereos S, et al. Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia. Chest. 2005;127(5):1523–1530
  75. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous β-thalassemia. The New England Journal of Medicine. 1994;331:574–578
  76. Cunningham MJ, Macklin EA, Neufeld EJ, et al. Thalassemia clinical research network. complications of beta-thalassemia major in North America. Blood. 2004;104(1):34–39
  77. Du ZD, Roguin N, Milgram E, et al. Pulmonary hypertension in patients with thalassemia major. American Heart Journal. 1997;134:532–537
  78. Kholova I, Niessen HW. Amyloid in the cardiovascular system: a review. Journal of Clinical Pathology. 2005;58(2):125–133[Review]
  79. Chow LQ, Bahlis N, Russell J, et al. Autologous transplantation for primary systemic AL amyloidosis is feasible outside a major amyloidosis referral centre: the Calgary BMT Program experience. Bone Marrow Transplantation. 2005;36(7):591–596
  80. Bahlis NJ, Lazarus HM. Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted?. Bone Marrow Transplantation. 2006;38(1):7–15
  81. Moreau P, Leblond V, Bourquelot P, et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. British Journal of Haematology. 1998;101(4):766–769
  82. Sanchorawala V, Wright DG, Seldin DC, et al. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplantation. 2001;28(7):637–642[Review]
  83. Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. Journal of Clinical Oncology. 2004;22(18):3751–3757
  84. Gatzoulis MA, Vellodi A, Redington AN. Cardiac involvement in mucopolysaccharidoses: effects of allogeneic bone marrow transplantation. Archives of Disease in Childhood. 1995;73(3):259–260
  85. Platzbecker U, Klingel K, Thiede C, et al. Acute heart failure after allogeneic blood stem cell transplantation due to massive myocardial infiltration by cytotoxic T cells of donor origin. Bone Marrow Transplantation. 2001;27:107–109
  86. Prevost D, Taylor G, Sanatani S, et al. Coronary vessel involvement by chronic graft-versus-host disease presenting as sudden cardiac death. Bone Marrow Transplantation. 2004;34:655–656
  87. Roberts SS, Leeborg N, Loriaux M, et al. Acute graft-versus-host disease of the heart. Pediatric Blood & Cancer. 2006;47(5):624–628
  88. Rackley C, Schultz KR, Goldman FD, et al. Cardiac manifestations of graft-versus-host disease. Biology of Blood and Marrow Transplantation. 2005;11:773–780
  89. Chiang KY, Lazarus HM. Should we be performing more combined hematopoietic stem cell plus solid organ transplants?. Bone Marrow Transplantation. 2003;31:633–642[Review]
  90. Ramrakha PS, Marks DI, O'Brien SG, et al. Orthotopic cardiac transplantation for dilated cardiomyopathy after allogeneic bone marrow transplantation. Clinical Transplantation. 1994;8:23–26
  91. Kottaridis PD, Milligan DW, Chopra R, et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood. 2000;96:2419–2425
  92. Chakraverty R, Peggs K, Chopra R, et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood. 2002;99:1071–1078
  93. Ritchie DS, Seymour JF, Roberts AW, et al. Acute left ventricular failure following melphalan and fludarabine conditioning. Bone Marrow Transplantation. 2001;28:101–103
  94. Oshima K, Sakata-Yanagimoto M, Asano-Mori Y, et al. Cardiac complications after haploidentical HLA-mismatched hematopoietic stem cell transplantation using in vivo alemtuzumab. Bone Marrow Transplantation. 2005;36:821–824

PII: S1521-6926(06)00065-X

doi: 10.1016/j.beha.2006.09.005

Best Practice & Research Clinical Haematology
Volume 20, Issue 2 , Pages 247-263 , June 2007

Article Tools

* Image Usage & Resolution